Pricing Log in Create free account
Friday 6 November 2026 Export CYTK’s income statement to Excel — free account

Cytokinetics, Incorporated

CYTK Healthcare Biotechnology

Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024.

Revenue
+2,356.5%
EPS
+46.3%
Free cash flow
−6.73%
Total debt
−83.9%

Quarter to September 2026, against a year earlier

54.93 0.62 −1.12%
Market cap
$7.7B
P/E
0.0×
Fwd P/E
−10.3×
Dividend yield
—
F-score
2/9
Altman Z
−1.98
Beneish M
−0.44
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Cytokinetics, Incorporated (CYTK) EV/EBITDA

Alert me on EV/EBITDA

Cytokinetics, Incorporated has no meaningful EV/EBITDA: its trailing twelve-month EBITDA is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 171× (December 2016) — the current reading is the lowest in ten years.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 19.0× —

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 0.0× —
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
43 more quarters

Against its own ten years

Low 0.0× High 171×
Ten-year median 0.0×
Current reading's percentile 94

EV/EBITDA against peers

Company EV/EBITDA
TWST Twist Bioscience Corporation compare n/m
SYRE Spyre Therapeutics, Inc. compare n/m
CYTK Cytokinetics, Incorporated n/m
MDGL Madrigal Pharmaceuticals, Inc. compare n/m
ARWR Arrowhead Pharmaceuticals, Inc. compare n/m
KRYS Krystal Biotech, Inc. compare 34.1×
CAI Caris Life Sciences,�Inc. compare 39.4×
CORT Corcept Therapeutics Incorporated compare 67.4×
PTGX Protagonist Therapeutics, Inc. compare 145×
Biotechnology industry median 0.7×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on CYTK